Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the latter part of the year.
source
Sponsor:News technical sponsor
Sponsor:News AI sponsor
Sponsor: AI sponsor
Sponsor: AI sponsor

Leave a Comment

Vélemény, hozzászólás?

Az e-mail címet nem tesszük közzé. A kötelező mezőket * karakterrel jelöltük